The challenges of severe pneumonia: new pathogens, new drugs and new formulations

M. Niederman (New York, United States of America)

Source: Virtual Congress 2021 – Respiratory infections
Session: Respiratory infections
Session type: State of the art session
Number: 1235

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Niederman (New York, United States of America). The challenges of severe pneumonia: new pathogens, new drugs and new formulations. Virtual Congress 2021 – Respiratory infections

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Atypical mycobacteriosis : new drugs, new strategies
Source: Annual Congress 2004 - PG11 - Multiresistant tuberculosis and atypical mycobacterial disease
Year: 2004

From the bedside: upcoming new clinical strategies: novel strategies to combat respiratory viral infections
Source: International Congress 2017 – Scientific year in review
Year: 2017

HAP/VAP : new guidelines, new approaches
Source: International Congress 2018 – Chinese Programme 2018: Part II
Year: 2018

Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries?
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015

Improved diagnostics and diagnostic approaches: The role in the fight to emerging infectious diseases (EID) and antimicrobial resistance (AMR)
Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions
Year: 2021

CF microbiology, emerging pathogens and more treatment options
Source: Annual Congress 2013 –PG20 Cystic fibrosis: an update of the basic defects and clinical problems in CF children and adults
Year: 2013

Treating sarcoidosis and potential new drugs
Source: Eur Respir Monogr 2022; 96: 328-336
Year: 2022

Economic aspects of enhanced testing strategies for respiratory diseases
Source: Value-Dx event 2021: Community-acquired respiratory tract infections: where do we stand in 2021, ECCMID 2021
Year: 2021

Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones},
Source: Eur Respir J 2012; 40: 814-822
Year: 2012

Therapeutic strategies in pneumonia: going beyond antibiotics
Source: Eur Respir Rev 2015; 24: 516-524
Year: 2015

Rational use of new TB drugs in the EU
Source: Annual Congress 2012 - New guidelines in respiratory infections
Year: 2012

Fate or missed opportunities - challenges in diagnosing paediatric drug resistant tuberculosis in Germany
Source: Virtual Congress 2021 – Paediatric respiratory infections: chronic infection, vaccination and lung function
Year: 2021

Antibiotic resistance in respiratory infections: challenges and actions for the upcoming decade
Source: Virtual Congress 2021 – Respiratory infections
Year: 2021

Tuberculosis elimination, patients' lives and rational use of new drugs: revisited
Source: Eur Respir J 2016; 47: 664-667
Year: 2016

The role of inhaled antibiotics in bronchial infection
Source: Eur Respir Monogr 2013; 60: 120-126
Year: 2013

Novel NTM treatments and approaches, repurposed to bacteriophages
Source: Virtual Congress 2021 – New insights into nontuberculous mycobacteria disease: from diagnosis to treatment
Year: 2021